Sex differences in the course of schizophrenia across diverse regions of the world
- PMID: 27881918
- PMCID: PMC5115683
- DOI: 10.2147/NDT.S101151
Sex differences in the course of schizophrenia across diverse regions of the world
Abstract
This study explores sex differences in the outcomes of patients with schizophrenia (clinical/functional remission and recovery) across diverse regions of the world (Northern Europe, Southern Europe, Central and Eastern Europe, Latin America, East Asia, and North Africa and the Middle East). Data (n=16,380 for this post hoc analysis) were taken from the World-Schizophrenia Health Outcomes Study. In most regions, females had a later age at first service contact for schizophrenia, a lower level of overall/negative symptom severity, lower rates of alcohol/substance abuse and paid employment, and higher percentages of having a spouse/partner and independent living. Overall, females had slightly higher rates of clinical remission (58.0% vs 51.8%), functional remission (22.8% vs 16.0%), and recovery (16.5% vs 16.0%) at 36 months (P<0.001 for all). This pattern was consistently observed in Southern Europe and Northern Europe even after controlling for baseline sex differences, but not in other regions. In Central and Eastern Europe, rates of clinical remission were higher in females at 36 months, but those of functional remission and recovery were similar between males and females. The opposite was observed for Latin America. In East Asia, sex differences were rarely observed for these outcomes. Finally, in North Africa and the Middle East, sex differences in these outcomes were pronounced only in regression analyses. These regional variations shed light on the importance of psychosocial and cultural factors and their effects on sex in the prognosis of schizophrenia.
Keywords: recovery; region; remission; schizophrenia; sex; world.
Conflict of interest statement
DisclosureDN, WM, and TT are employees of Eli Lilly and Company. JMH has acted as a consultant, received grants, or acted as a speaker in activities sponsored by the following companies: Astra-Zeneca, Eli Lilly and Company, Glaxo-Smith-Kline, and Lundbeck. MVM conducted the statistical analysis under a contract between Fundació Sant Joan de Déu and Eli Lilly and Company. The authors declare no other conflicts of interest in this work.
Figures



Similar articles
-
Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study.Br J Psychiatry. 2011 Sep;199(3):194-201. doi: 10.1192/bjp.bp.110.082065. Br J Psychiatry. 2011. PMID: 21881098
-
Regional differences in treatment response and three year course of schizophrenia across the world.J Psychiatr Res. 2012 Jul;46(7):856-64. doi: 10.1016/j.jpsychires.2012.03.017. Epub 2012 May 9. J Psychiatr Res. 2012. PMID: 22575332
-
World health-related indicators.World Health Stat Rep. 1976;29(12):682-97. World Health Stat Rep. 1976. PMID: 1014713 English, French.
-
Estimating the number of men who have sex with men in low and middle income countries.Sex Transm Infect. 2006 Jun;82 Suppl 3(Suppl 3):iii3-9. doi: 10.1136/sti.2005.019489. Sex Transm Infect. 2006. PMID: 16735290 Free PMC article. Review.
-
Heterosexual transmission of HIV.AIDS. 1988;2 Suppl 1:S49-56. doi: 10.1097/00002030-198800001-00008. AIDS. 1988. PMID: 3147680 Review.
Cited by
-
Alcohol use in Tanzanians with chronic psychotic disorders and poor medication adherence.S Afr J Psychiatr. 2021 Mar 19;27:1570. doi: 10.4102/sajpsychiatry.v27i0.1570. eCollection 2021. S Afr J Psychiatr. 2021. PMID: 33824753 Free PMC article.
-
Does Gender Influence Outcome in Schizophrenia?Psychiatr Q. 2019 Mar;90(1):173-184. doi: 10.1007/s11126-018-9619-y. Psychiatr Q. 2019. PMID: 30484001 Review.
-
Employment trajectories until midlife in schizophrenia and other psychoses: the Northern Finland Birth Cohort 1966.Soc Psychiatry Psychiatr Epidemiol. 2023 Jan;58(1):65-76. doi: 10.1007/s00127-022-02327-6. Epub 2022 Jul 7. Soc Psychiatry Psychiatr Epidemiol. 2023. PMID: 35796815 Free PMC article.
-
Early-life factors associated with increased risk of disability pension in the national real-world schizophrenia FACE-SZ cohort study.Eur Arch Psychiatry Clin Neurosci. 2022 Oct;272(7):1379-1384. doi: 10.1007/s00406-021-01364-7. Epub 2022 Mar 25. Eur Arch Psychiatry Clin Neurosci. 2022. PMID: 35333961
-
Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review.Front Psychiatry. 2021 Dec 22;12:789179. doi: 10.3389/fpsyt.2021.789179. eCollection 2021. Front Psychiatry. 2021. PMID: 35002807 Free PMC article. Review.
References
-
- Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984;41(10):949–958. - PubMed
-
- Angermeyer MC, Goldstein JM, Kuehn L. Gender differences in schizophrenia: rehospitalization and community survival. Psychol Med. 1989;19(2):365–382. - PubMed
-
- Goldstein JM. Gender differences in the course of schizophrenia. Am J Psychiatry. 1988;145(6):684–689. - PubMed
-
- Haro JM, Novick D, Bertsch J, Karagianis J, Dossenbach M, Jones PB. Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study. Br J Psychiatry. 2011;199(3):194–201. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources